Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05287360 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants
A Phase 1 study, sponsored by Elevar Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT05287360 is a Phase 1 study that has completed, run by Elevar Therapeutics. The registered enrollment target is 60 participants.
The verdict
NCT05287360, a Phase 1 study, has completed, sponsored by Elevar Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The main purpose of this trial is to compare a single dose of 4 different rivoceranib tablets in healthy adult participants.
Interventions
- DRUG Rivoceranib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-12-30 |
| Est. Completion | 2022-03-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05287360
The ClinicalTrials.gov registry entry for NCT05287360 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elevar Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rivoceranib is the first listed.
NCT05287360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05287360 about?
NCT05287360 is a clinical study titled "A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants". The main purpose of this trial is to compare a single dose of 4 different rivoceranib tablets in healthy adult participants.
What is the current status of trial NCT05287360?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2021-12-30. Estimated completion is 2022-03-24.
What interventions are being tested in trial NCT05287360?
The interventions under investigation include: Rivoceranib (DRUG).
Who is sponsoring clinical trial NCT05287360?
This trial is sponsored by Elevar Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.